Form 4: Bicara Therapeutics Director, Jake Simson, Acquires Stock Options

Director Jake Simson of Bicara Therapeutics acquired stock options exercisable for 23,746 shares of common stock on September 12, 2024.

Summary

• Jake Simson, a director at Bicara Therapeutics Inc., filed a Form 4 on September 16, 2024, reporting a transaction.
• On September 12, 2024, Simson acquired stock options for 23,746 shares of Bicara Therapeutics' common stock at an exercise price of $18.
• The options vest upon the earlier of August 16, 2025, or the date of the next Annual Meeting of Stockholders, contingent on continued service.
• Simson holds the option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P., and will turn over any proceeds from exercising the option to offset advisory fees owed by these funds.
• Simson disclaims beneficial ownership of the option and underlying common stock due to this arrangement.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock, providing transparency to the market.

Related Party Transactions

• The Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the 'Fund') and R.A. Capital Nexus Fund III, L.P. (the 'Nexus Fund III').
• The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund III to the Adviser.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The arrangement with RA Capital Management impacts the advisory fees owed by the Fund and Nexus Fund III.

Key Dates